HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies
暂无分享,去创建一个
Dong Soo Yun | Daniel W. Kulp | D. Irvine | Xiaozhen Hu | D. Burton | I. Wilson | M. Nussenzweig | W. Schief | B. Briney | A. Ward | O. Kalyuzhniy | Yumiko Adachi | R. Stanfield | N. Freund | G. Ozorowski | S. Menis | Meaghan Jones | A. Escolano | T. Tokatlian | L. McCoy | F. Garces | P. Dosenovic | J. Steichen | Andrew A. Mutafyan | Erik Georgeson | M. Kubitz | Bryan S. Briney | T. Schiffner | Alexander D. Gitlin | C. Mayer | Torben Schiffner
[1] Daniel W. Kulp,et al. Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice , 2016, Cell.
[2] D. Burton,et al. Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design , 2016, PLoS pathogens.
[3] C. Soto,et al. Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody , 2016, Science.
[4] Dennis R Burton,et al. Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design. , 2016, Annual review of immunology.
[5] Joseph G. Jardine,et al. HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen , 2016, Science.
[6] John P. Moore,et al. HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies. , 2016, Trends in immunology.
[7] L. Stamatatos,et al. Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice , 2016, Nature Communications.
[8] Ben Murrell,et al. Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort , 2016, PLoS pathogens.
[9] Jonathan R. McDaniel,et al. Structures of HIV-1-Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design , 2015, Nature Structural &Molecular Biology.
[10] Robyn L Stanfield,et al. Affinity Maturation of a Potent Family of HIV Antibodies Is Primarily Focused on Accommodating or Avoiding Glycans. , 2015, Immunity.
[11] D. Burton,et al. Identification of Common Features in Prototype Broadly Neutralizing Antibodies to HIV Envelope V2 Apex to Facilitate Vaccine Design. , 2015, Immunity.
[12] A. McDowall,et al. Broadly Neutralizing Antibody 8ANC195 Recognizes Closed and Open States of HIV-1 Env , 2015, Cell.
[13] John P. Moore,et al. Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity , 2015, Journal of Virology.
[14] David Nemazee,et al. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen , 2015, Science.
[15] G. Debnath,et al. D-101 HIV-1 neutralizing antibodies induced by native-like envelope trimers , 2016 .
[16] Young Do Kwon,et al. Crystal structure , conformational fixation , and entry-related interactions of mature ligand-free HIV-1 Env , 2016 .
[17] Daniel W. Kulp,et al. Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice , 2015, Cell.
[18] John P. Moore,et al. A Native-Like SOSIP.664 Trimer Based on an HIV-1 Subtype B env Gene , 2015, Journal of Virology.
[19] L. Stamatatos,et al. Antigen modification regulates competition of broad and narrow neutralizing HIV antibodies , 2014, Science.
[20] Tongqing Zhou,et al. Structure and immune recognition of trimeric prefusion HIV-1 Env , 2014, Nature.
[21] John P. Moore,et al. Structural Evolution of Glycan Recognition by a Family of Potent HIV Antibodies , 2014, Cell.
[22] J. Mascola,et al. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques , 2014, The Journal of experimental medicine.
[23] Scott D Boyd,et al. Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodies. , 2014, Cell host & microbe.
[24] Wayne C Koff,et al. Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. , 2014, Immunity.
[25] Chaim A. Schramm,et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies , 2014, Nature.
[26] Florian Klein,et al. Structural Insights on the Role of Antibodies in HIV-1 Vaccine and Therapy , 2014, Cell.
[27] Gwo-Yu Chuang,et al. Antibodies VRC01 and 10E8 Neutralize HIV-1 with High Breadth and Potency Even with Ig-Framework Regions Substantially Reverted to Germline , 2014, The Journal of Immunology.
[28] Jingdong Tian,et al. Circular polymerase extension cloning. , 2014, Methods in molecular biology.
[29] John P. Moore,et al. Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer , 2013, Science.
[30] John P. Moore,et al. Cryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer , 2013, Science.
[31] Daphne Koller,et al. The Effects of Somatic Hypermutation on Neutralization and Binding in the PGT121 Family of Broadly Neutralizing HIV Antibodies , 2013, PLoS pathogens.
[32] M. Nussenzweig,et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia , 2013, Nature.
[33] Michael S. Seaman,et al. Therapeutic Efficacy of Potent Neutralizing HIV-1-Specific Monoclonal Antibodies in SHIV-Infected Rhesus Monkeys , 2013, Nature.
[34] Florian Klein,et al. Antibodies in HIV-1 Vaccine Development and Therapy , 2013, Science.
[35] John P. Moore,et al. A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies , 2013, PLoS pathogens.
[36] L. Stamatatos,et al. Correction: Recombinant HIV Envelope Proteins Fail to Engage Germline Versions of Anti-CD4bs bNAbs , 2013, PLoS Pathogens.
[37] B. Haynes,et al. HIV‐1 neutralizing antibodies: understanding nature's pathways , 2013, Immunological reviews.
[38] David Nemazee,et al. Rational immunogen design to target specific germline B cell receptors , 2012, Retrovirology.
[39] L. Stamatatos,et al. Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies , 2013, The Journal of experimental medicine.
[40] Tongqing Zhou,et al. Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization , 2013, Cell.
[41] Chaim A. Schramm,et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus , 2013, Nature.
[42] L. Stamatatos,et al. Recombinant HIV Envelope Proteins Fail to Engage Germline Versions of Anti-CD4bs bNAbs , 2013, PLoS pathogens.
[43] J. Mascola,et al. Anti-HIV B Cell Lines as Candidate Vaccine Biosensors , 2012, The Journal of Immunology.
[44] Michael S. Seaman,et al. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies , 2012, Proceedings of the National Academy of Sciences.
[45] D. Burton,et al. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo , 2012, Proceedings of the National Academy of Sciences.
[46] Thomas B Kepler,et al. B-cell–lineage immunogen design in vaccine development with HIV-1 as a case study , 2012, Nature Biotechnology.
[47] S. Zolla-Pazner,et al. Human Anti-V3 HIV-1 Monoclonal Antibodies Encoded by the VH5-51/VL Lambda Genes Define a Conserved Antigenic Structure , 2011, PLoS ONE.
[48] Pham Phung,et al. Broad neutralization coverage of HIV by multiple highly potent antibodies , 2011, Nature.
[49] Ron Diskin,et al. Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding , 2011, Science.
[50] Mario Roederer,et al. Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing , 2011, Science.
[51] Maxim N. Artyomov,et al. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation , 2010, Nature.
[52] Tongqing Zhou,et al. Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01 , 2010, Science.
[53] J. Mascola,et al. Crystal Structure of PG16 and Chimeric Dissection with Somatically Related PG9: Structure-Function Analysis of Two Quaternary-Specific Antibodies That Effectively Neutralize HIV-1 , 2010, Journal of Virology.
[54] D. Dimitrov. Therapeutic antibodies, vaccines and antibodyomes , 2010, mAbs.
[55] Pham Phung,et al. Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target , 2009, Science.
[56] D. Dimitrov,et al. Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: Implications for evasion of immune responses and design of vaccine immunogens , 2009, Biochemical and Biophysical Research Communications.
[57] Richard T. Wyatt,et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals , 2009, Nature.
[58] S. Roffler,et al. Directed evolution of a lysosomal enzyme with enhanced activity at neutral pH by mammalian cell-surface display. , 2008, Chemistry & biology.
[59] D. Trono,et al. Production and Titration of Lentiviral Vectors , 2006, Current protocols in neuroscience.
[60] Renate Kunert,et al. Cardiolipin Polyspecific Autoreactivity in Two Broadly Neutralizing HIV-1 Antibodies , 2005, Science.
[61] C. Barbas,et al. Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. , 1992, Proceedings of the National Academy of Sciences of the United States of America.